Slide 1Absolute Risk Reduction, Number Needed to Treat, Back-of-the-Envelope Cost Effectiveness Analysis, Testing Thresholds Revisited 26 October 2006 Michael A. Kohn, MD,…

Slide 1Diabetes mellitus: An update D. Hunt March 2010 Slide 2 Significance of diabetes mellitus 5% of the population has diagnosed diabetes prevalence increases with age:…

Slide 1VTE prevention: Real-world outcome data Domenico Pagano Consultant Cardiothoracic Surgeon Clinical Director Quality & Outcomes Research Unit University Hospital…

Slide 1Reporting drugs and treatments Thomas Abraham JMSC 6090 Slide 2 What we will learn today How to evaluate and report on studies The difference between absolute and…

Folie 1 Results of the Longest and Largest Ever -Blockade Study in CHF Mortality Reduction beyond ß 1 -Blockade Pub.: Results: Poole-Wilson et al. Lancet 2003;362:7-13 Design:…

1. Disclosure William Marston, M.D. I disclose the following financial relationship(s): •Consultant/Advisory Board: Advanced BioHealing, BSN Jobst 2. Venous leg ulcers:…

1. Clinical evidence – based safety and efficacy of a biolimus eluting stent with biodegradable polymer technology Maurizio D’Amico MD Cardiovascular Department Molinette…

1. Shock Gordon R. Bernard, M.D. Division of Allergy, Pulmonary, and Critical Care Medicine Vanderbilt University 2. Overall Objectives • Understand the pathophysiology…

1. Osteoporosis management Efficacy and safety of yearly bisphosphonate 2. Osteoporosis Increase morbidity and mortality 3. Who to treat ? Prior h/o hip/vertebral # or T…

1. Impact of Obesity on Cardiometabolic Risk: Will We Lose the Battle? Richard Nesto, MD, FACC, FAHAChair, Department of Cardiovascular Medicine Lahey Clinic Medical Center,…